TRIB2 and prostate carcinoma: We also found that overexpression of TRIB2 alone makes prostate cancer cells resistant to therapeutic doses of enzalutamide, and the enzalutamide-resistant cells are not sensitive to the synthetic androgen, R1881 (Figs. 3D and S5).